Clinical Trial Update: Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating inaticabtagene autoleucel for refractory systemic lupus erythematosus-related immune thrombocytopenia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia
• Systemic Lupus Erythematosus

Drugs mentioned

• Inaticabtagene Autoleucel

Snippet

Sponsor: Juventas Cell Therapy Ltd. | Conditions: Autoimmune Thrombocytopenia | Phase 1 | Status: RECRUITING